Table 3.
Characteristics of patients who had done curative surgery without neoadjuvant therapy (n=1,928)
| Variable | Pre-COVID (2017–2019) | COVID (2020) | P-value |
|---|---|---|---|
| No. of patients | 1,522 | 406 | |
| Agea (yr) | 62 (19–89) | 62 (17–92) | 0.235 |
| Sex | 0.943 | ||
| Male | 854 (56.1) | 227 (55.9) | |
| Female | 668 (43.9) | 179 (44.1) | |
| Body mass indexb (kg/m2) | 23.92 (14.41–37.27) | 23.84 (12.75–44.69) | 0.893 |
| ASA PS classification | 0.650 | ||
| I | 438 (28.8) | 114 (28.1) | |
| II | 963 (63.3) | 255 (62.8) | |
| III | 115 (7.6) | 34 (8.4) | |
| IV | 5 (0.3) | 3 (0.7) | |
| Hereditary colon cancer | 0.335 | ||
| HNPCC | 13 (0.9) | 4 (1.0) | |
| FAP | 6 (0.4) | 4 (1.0) | |
| Preoperative CEAa (ng/mL) | 1.69 (0.5–342.86) | 2.87 (0.3–268.00) | < 0.0001 |
| Elevated preoperative CEA, > 5 ng/mL | 196 (12.9) | 118 (29.1) | < 0.0001 |
| Character of surgery | > 0.999 | ||
| Elective | 1,518 (99.7) | 405 (99.8) | |
| Emergent | 4 (0.3) | 1 (0.2) | |
| Cancer obstruction | 202 (13.3) | 56 (13.8) | 0.784 |
| Cancer perforation | 18 (1.2) | 5 (1.2) | > 0.999 |
| TNM stage | 0.167 | ||
| 0+I | 409 (27.0) | 118 (29.3) | |
| II | 511 (33.8) | 116 (28.8) | |
| III | 594 (39.2) | 169 (41.9) | |
| T classification | 0.448 | ||
| Tis + T1 | 276 (18.2) | 86 (21.3) | |
| T2 | 230 (15.2) | 62 (15.3) | |
| T3 | 783 (51.7) | 193 (47.8) | |
| T4 | 226 (14.9) | 63 (15.6) | |
| N classification | 0.329 | ||
| N0 | 914 (60.5) | 235 (58.3) | |
| N1 | 430 (28.5) | 113 (28.0) | |
| N2 | 166 (11.0) | 55 (13.6) | |
| Stage I + II (n = 1,123) | 897 | 226 | |
| Lymphatic invasion | 134 (14.9) | 50 (22.1) | 0.009 |
| Perineural invasion | 265 (29.5) | 56 (24.8) | 0.157 |
| Vascular invasion | 16 (1.8) | 5 (2.2) | 0.592 |
| Tumor budding | 275 (30.7) | 63 (27.9) | 0.415 |
Values are presented as number only, amedian (range), number (%), or bmean (range).
COVID, coronavirus disease; ASA, American Society of Anesthesiologists; PS, physical status; HNPCC, hereditary nonpolyposis colorectal cancer; FAP, familial adenomatous polyposis; CEA, carcinoembryonic antigen.